The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Completion of Therapy by Medicare Patients With Stage III Colon Cancer
Open accessAbstract
BACKGROUND: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. METHODS: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. RESULTS: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. CONCLUSIONS: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“especially lung and gastrointestinal cancers which have a poor prognosis and high symptom profile (12, 13).”
From Coping in Patients With Incurable Lung and Gastrointestinal Cancers: A Validation Study of the Brief COPE (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
(2016) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,300
(2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,375
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,719
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Adjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 981
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 924
Research works printed but not linked: 2
- Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J. The relative efficacy of 5-FU+leucovorin (FU-LV), 5-FU+levamisole (FU-LEV) and 5-FU+leucovorin+levamisole (FU-LV-LEV) in patients with Ducke's B and C carcinoma of the colon: first report of NSABP C-04 Proc ASCO 1996 ;15:205.
- Bower M, Asbury R, Kramer Z, Pandya K, Bennett JM. Adjuvant chemotherapy for colorectal cancer in the elderly: population-based experience. Proc ASCO1993 ; 12 : 195 (Abs #570).
Cited by
Sorted by citations
Hershman, D. L., Kushi, L. H., Shao, T. H., Buono, D. L., Kershenbaum, A., Tsai, W., Fehrenbacher, L., Gomez, S. L., Miles, S. Q., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 834
Sex- and gender-specific disparities in colorectal cancer risk
Kim, S.-E. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5167 · Cited by 497
Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
O’Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J., Heise, C. P., & Smith, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3426 · Cited by 463
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review
Puts, M. T. E., Tu, H. A., Tourangeau, A. E., Howell, D., Fitch, M. I., Springall, E., & Alibhai, S. M. H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt433 · Cited by 236
Social Support and Chronic Kidney Disease: An Update
Cohen, S. D., Sharma, T., Acquaviva, K., Peterson, R. A., Patel, S. S., & Kimmel, P. L. (2007) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2007.04.007 · Cited by 188
Metadata
- Authors
- Dobie, S. A., Baldwin, L.-M., Dominitz, J. A., Matthews, B., Billingsley, K., & Barlow, W.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Dobie, Sharon A.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-05-03
- Volume
- 98
- Issue
- 9
- Pages
- 610-619
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3124351
- OpenAlex
- W2108822192
- Cited by
- 150
- References
- 53
- Citations by year
- 2026: 2 · 2024: 5 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 13 · 2013: 11 · 2012: 11
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA089544)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- stage III colon cancer, adjuvant chemotherapy, chemotherapy completion, Medicare beneficiaries, cancer mortality, predictors of treatment completion, patient characteristics, physician characteristics, SEER, Medicare claims data
- MeSH terms
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Female, Medicare, Humans, Male, Neoplasm Staging, Patient Compliance, Predictive Value of Tests, Risk Factors, Social Support, United States, Reproducibility of Results, Logistic Models, Frail Elderly, Chemotherapy, Adjuvant, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
